Fig. 4From: High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective studyDifferences in mutation abundances in tumor and ctDNA at baseline between patients with overall survival (A) and progression-free survival (B) < versus ≥ 6 monthsBack to article page